

Timing of Complete Multivessel Revascularization in Patients Presenting with Non-ST-Elevation Acute Coronary Syndrome

Jacob J. Elscot, BSc¹; Hala Kakar, MD¹; Paola Scarparo, MD¹; Wijnand K. den Dekker, MD, PhD¹; Johan Bennett, MD, PhD²; Carl E. Schotborgh MD³; Rene van der Schaaf, MD, PhD⁴; Manel Sabaté MD, PhD⁵; Raúl Moreno MD, PhD⁶; Koen Ameloot, MD, PhD⁷; Rutger J. van Bommel, MD, PhD⁸; Daniele Forlani MD⁹; Bert Van Reet, MD¹⁰; Giovanni Esposito, MD, PhD¹¹; Maurits T. Dirksen, MD, PhD¹²; Willem P.T. Ruifrok MD, PhD¹³; Bert R. C. Everaert MD, PhD¹⁴; Carlos Van Mieghem, MD, PhD¹⁵; Eduardo Pinar, MD, PhD¹⁶; Fernando Alfonso, MD, PhD¹⁷; Paul Cummins, RN¹; Mattie Lenzen, PhD¹; Salvatore Brugaletta, MD, PhD⁷; Joost Daemen, MD, PhD¹; Eric Boersma, PhD¹; Nicolas M. Van Mieghem, MD, PhD¹; Roberto Diletti, MD, PhD¹; for the BIOVASC Investigators

¹ Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands

² Department of Cardiovascular Medicine, University Hospital Leuven, Leuven, Belgium

³ Department of Cardiology, Haga Hospital, The Hague, The Netherlands

⁴ Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands

⁵ Interventional Cardiology Department, Cardiovascular Institute, Hospital Clinic, Barcelona, Spain

⁶ Interventional Cardiology Unit, Cardiology Department, La Paz University Hospital, Paseo de la Castellana, Spain

⁷ Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos, 3600 Genk, Belgium

⁸ Department of Cardiology, Tergooi MC, Hilversum, The Netherlands

⁹ Department of Cardiology, Santo Spirito Hospital, Pescara, Italy

¹⁰ Department of Cardiology, AZ Turnhout, Turnhout, Belgium

¹¹ Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy

¹² Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands

¹³ Department of Cardiology, Treant Zorggroep, Emmen, The Netherlands

¹⁴ Department of Cardiology, AZ Monica Hospital, Antwerp, Belgium

¹⁵ Department of Cardiology, AZ Groeninge, Kortrijk, Belgium

¹⁶ Department of Cardiology, Interventional Cardiology Unit, Virgen de la Arrixaca Hospital, Murcia, Spain

¹⁷ Department of Cardiology, Hospital Universitario de La Princesa Madrid, CIBER-CV, Madrid, Spain

Address for correspondence

Roberto Diletti, MD, PhD

Interventional Cardiology, Thoraxcenter, Erasmus MC

Dr. Molewaterplein 40,

3015 GD Rotterdam, The Netherlands

Visiting address: office Rg-632k

Telephone 0031 10 703 52 60

Fax 0031 10 703 52 54

E-mail: r.diletti@erasmusmc.nl

Word count (including references): 6133

45 **Disclosures**

46
47 RD has received institutional research grants from Biotronik, Medtronic, ACIST Medical Systems, and Boston
48 Scientific. WKdD has received institutional research grants from Biotronik. NMVM has received institutional
49 research grants from Biotronik, Abbott, Medtronic, Edwards Lifesciences, PulseCath, Abiomed, and Daiichi
50 Sankyo; speaker fees from Abiomed and Amgen; and a travel grant from JenaValve. JB has received institutional
51 grants from Biotronik, Abbott Vascular and Shockwave Medical. JD has received institutional grant/research
52 support from Abbott Vascular, Boston Scientific, ACIST Medical, Medtronic, Microport, Pie Medical, and ReCor
53 medical, and consultancy and speaker fees from Abbott Vascular, Abiomed, ACIST medical, Boston Scientific,
54 Cardialysis BV, CardiacBooster, Kaminari Medical, ReCor Medical, PulseCath, Pie Medical, Sanofi, Siemens
55 Health Care and Medtronic. All other authors declare no competing interests.

56

57 **Abstract**

58

59 *Background*

60 Multivessel coronary artery disease (MVD) is highly prevalent in patients presenting with non-ST-segment elevation
61 myocardial infarction (NSTEMI-ACS) and is associated with worse clinical outcomes compared with single vessel
62 disease patients. Complete revascularization of the culprit and all significant non-culprit lesions reduces the
63 incidence of major adverse cardiac events, but the optimal timing of non-culprit artery revascularization remains
64 unclear.

65

66 *Methods*

67 This prespecified substudy of the randomized BIOVASC trial included patients who presented with NSTEMI-ACS and
68 MVD, defined as ≥ 1 non-culprit related coronary artery with a diameter of ≥ 2.5 mm and $\geq 70\%$ stenosis as per
69 visual estimation or positive coronary physiology testing. Risk differences of the composite of all-cause mortality,
70 myocardial infarction, unplanned ischemia driven revascularization or cerebrovascular events and its individual
71 components were compared between the patients who were randomized to immediate and staged complete
72 revascularization at 30 days and 1 year.

73

74 *Results*

75 The BIOVASC trial enrolled 1525 patients, 917 patients presented with NSTEMI-ACS, of whom 459 were allocated to
76 the immediate complete and 458 to the staged complete revascularization group. The incidences of the primary
77 composite outcome were similar in the two groups (7.9% vs. 10.1%, risk difference 2.2%, 95%CI -1.5 to 6.0, $p =$
78 0.24). Immediate complete revascularization was associated with a significant reduction in the incidence of
79 myocardial infarction (2.0% vs. 5.3%, risk difference 3.3%, 95% confidence interval [CI] 0.9 to 5.7, $p = 0.008$),
80 which was maintained after exclusion of procedure related myocardial infarctions occurring at the index or staged
81 procedure (2.0% vs. 4.4%, risk difference 2.4%, 95%CI 0.1 to 4.7, $p = 0.039$). Unplanned ischemia driven
82 revascularizations were also reduced in the immediate complete revascularization group (4.2% vs. 7.8%, risk
83 difference 3.5%, 95%CI 0.4 to 6.6, $p = 0.025$).

84

85 *Conclusions*

86 Immediate complete revascularization is safe in patients with NSTEMI-ACS and MVD and was associated with a
87 reduction in myocardial infarctions and unplanned ischemia driven revascularizations at 1 year.

88

89

90 **Clinical Perspective**

91

92 *What Is New?*

93

94 - This prespecified subanalysis of the BIOVASC trial shows that all spontaneous myocardial infarctions
95 between the index and staged procedure occurred in the population of patients that initially presented with
96 NSTEMI-ACS. At 30 days and 1 year patients randomized to immediate complete revascularization have
97 fewer myocardial infarctions and unplanned ischemia driven revascularizations.

98

99 *What Are the Clinical Implications?*

100

101 - Immediate complete revascularization appears to be a safe strategy and can be a reasonable option for
102 complete revascularization in patients presenting with NSTEMI-ACS and multivessel disease

103

104 - In patients presenting with NSTEMI-ACS and multivessel disease, misjudgment of the culprit lesion or
105 presence of multiple vulnerable plaques could have a role in the reduction of early occurring myocardial
106 infarctions when performing an immediate complete strategy.

107

108 **List of Abbreviations**

109

| | | |
|-----|----------|--|
| 110 | ACS | acute coronary syndrome |
| 111 | CI | confidence interval |
| 112 | ICR | immediate complete revascularization |
| 113 | MVD | multivessel disease |
| 114 | MI | myocardial infarction |
| 115 | NSTE-ACS | non-ST-segment elevation acute coronary syndrome |
| 116 | NSTEMI | non-ST-segment elevation myocardial infarction |
| 117 | PCI | percutaneous coronary intervention |
| 118 | PH | proportional hazards |
| 119 | SCR | staged complete revascularization |
| 120 | STEMI | ST-segment elevation myocardial infarction |
| 121 | UA | unstable angina |

122

123

124 **Introduction**

125
126 Multivessel coronary artery disease (MVD) is common in patients presenting with an acute coronary syndrome
127 (ACS) without persistent ST-elevations (NSTE-ACS). About 50% of the patients present with one or more
128 significant non-culprit lesions, a condition associated with a higher risk of myocardial infarction (MI), repeat
129 revascularization and mortality¹⁻⁵. An early invasive strategy is beneficial over a conservative approach in terms of
130 better clinical outcomes, especially in high risk patients⁶⁻¹⁰. Several retrospective studies suggested that complete
131 revascularization of both culprit and non-culprit lesions is associated with lower cumulative mortality rates and risk
132 of major adverse cardiac events^{3,11-13}. Therefore, recent guidelines report that complete revascularization should be
133 considered in patients with MVD and NSTE-ACS, tailored to patients' characteristics, preferences and
134 comorbidities¹⁴. However, the ideal timing of non-culprit revascularization in an immediate or staged setting
135 remains unclear. The ESC guidelines provide a class IIb recommendation for complete revascularization during
136 index percutaneous coronary intervention (PCI)¹⁴ based on one small randomized trial showing a lower risk of
137 MACE, driven by a lower repeat revascularization rate when immediate complete revascularization (ICR) was
138 performed instead of staged complete revascularization (SCR)¹⁵.

139 The recently published BIOVASC randomized trial showed that ICR is non-inferior to SCR in terms of a composite
140 of all-cause mortality, MI, any unplanned ischemia-driven revascularization or cerebrovascular events in patients
141 presenting with ACS at 1 year post index procedure.¹⁶

142 Against this background, we now present the trial results in the subcohort of NSTE-ACS patients, which was
143 prespecified in the protocol.

144
145

146 **Methods**

147

148 *Protocol Design and Randomization*

149 The BIOVASC trial was a multicenter, investigator-initiated, open-label randomized controlled non-inferiority trial
150 with participating sites in the Netherlands, Belgium, Italy and Spain, comparing ICR with SCR in patients
151 presenting with ACS and MVD. Details of the trial design and the main results have been previously reported^{16,17}. In
152 summary, 1525 patients presenting with acute coronary syndrome including both ST segment elevation myocardial
153 infarction (STEMI) and NSTEMI-ACS and multivessel MVD, defined as at least 70% stenosis in a non-culprit vessel \geq
154 2.5 mm in diameter by visual estimation or positive coronary physiology testing, were randomized in a 1:1 ratio to
155 ICR or SCR within 6 weeks after index procedure. Invasive coronary imaging or physiology assessment was
156 performed at the operator's discretion. Exclusion criteria consisted of the absence of a clear culprit, previous
157 coronary artery bypass grafting, cardiogenic shock and the presence of a chronic total occlusion in a vessel \geq 2.5
158 mm in diameter. The primary endpoint was a composite of all-cause mortality, nonfatal myocardial infarction, any
159 unplanned ischemia-driven revascularization, and cerebrovascular events at 1 year post index procedure.

160

161 *Prespecified analysis in patients with NSTEMI-ACS*

162 This BIOVASC substudy is a prespecified analysis designed to ascertain if there was a difference in clinical
163 outcomes when comparing ICR with SCR in the NSTEMI-ACS population. NSTEMI-ACS was defined according to
164 current guidelines¹⁴. In brief, a patient was considered presenting with NSTEMI-ACS if at least two of the following
165 criteria were present: 1) History consistent with new, or worsening ischemia, occurring at rest or with minimal
166 activity; 2) Coronary angiography with indication to PCI; 3) Electrocardiographic changes compatible with ischemia
167 but not diagnostic for ST-segment elevation myocardial infarction, (i.e. ST depression of 1 mm or greater in two
168 contiguous leads, T-wave inversion more than 3 mm, or any dynamic ST shifts). If cardiomyocyte necrosis was
169 present or absent, a patient would be categorized as presenting with non-ST-segment elevation myocardial infarction
170 (NSTEMI) or unstable angina (UA), respectively.

171

172

173 *Study endpoints*

174 Definitions of all efficacy and safety outcomes have been previously published in detail¹⁷. Deaths were classified as
175 cardiovascular or non-cardiovascular. If the cause of death was undetermined, it was considered cardiovascular. The
176 definition of MI was in line with the Third Universal Definition¹⁸, including a modification taking into account the
177 ACS setting similarly to the COMPLETE trial¹⁹. Repeat revascularization had to be considered both unplanned and
178 ischemia driven to be counted as an endpoint. A clinical events committee, comprising three independent physicians
179 with expertise in interventional cardiology or neurology, adjudicated all potential endpoints.

180
181 The primary outcome of the current analysis was a composite all-cause mortality, MI, unplanned ischemia driven
182 revascularization and cerebrovascular events, similar to the main trial. Secondary outcomes include the individual
183 components of the primary outcome composite and a composite of cardiovascular death and myocardial infarction.

184
185 *Statistical Analysis*

186 All randomized patients presenting with NSTEMI-ACS were included in the analysis as per an intention-to-treat
187 principle. Categorical data were presented as counts and percentages and tested by the chi-square test or Fisher exact
188 test if there was an expected cell value < 5. Continuous data were presented as mean and standard deviation if a
189 Gaussian distribution was present and tested by the unpaired t-test. Alternatively, continuous data were presented as
190 median and quartiles [Q1, Q3] and compared using the Mann-Whitney U test. The distribution of continuous data
191 was tested with the use of the Shapiro-Wilk test.

192 Cumulative time-to-event curves were calculated with the use of the Kaplan-Meier method. Patients were
193 censored after the first event had occurred or, if event-free, at the date on which they were last known to be alive.
194 Cox proportional hazard regression (PH) was conducted to further explore the relation between randomly allocated
195 treatment and study endpoints. Hazard ratios (HR) were presented with 95% confidence intervals and calculated
196 with use of Cox regression analyses. Assessment of the log-minus log survival plot led to a suspicion of a violated
197 PH assumption for the primary endpoint. Further testing of the Schoenfeld residuals concluded that the PH
198 assumption was not met. Therefore P values for all endpoints were computed on the difference in the cumulative
199 incidence between the two groups for consistency. A two-sided P value < 0.05 was considered statistically
200 significant. All analyses were performed using R version 4.2.1 (packages used: data.table, dplyr, ggplot2, ggpubr,
201 graphics, lubridate, stats, survival, survminer, tidycmprsk).

202

203 **Results**

204

205 *Patient characteristics*

206 The BIOVASC trial enrolled 1525 patients, of whom 917 (60.1%) presented with a NSTEMI or UA, with 459 and
207 458 patients randomized to ICR and SCR, respectively. ICR and SCR showed similar baseline characteristics
208 (Table 1). Investigator reported complete revascularization was more prevalent in the patients randomized to ICR,
209 despite intracoronary physiology and imaging being more frequently used in those randomized to SCR (Table 2).
210 Additionally, ICR was associated with a lower total stent length, contrast use, radiation dose and a shorter in-
211 hospital stay.

212

213 *Outcomes*

214 Follow up was complete in 456 (99.3%) and 452 (98.6%) patients randomized to ICR and SCR respectively.

215

216 At 30 days post index procedure, the primary composite outcome (1.8% vs. 5.7%, risk difference 4.0%, 95%
217 confidence interval [CI] 1.5 to 6.4, $p = 0.002$) and the composite of cardiovascular death and MI (0.2% vs. 3.1%,
218 risk difference 2.9%, 95%CI 1.1 to 4.6, $p = 0.001$) showed a statistically significant difference in favor of the
219 patients randomized to ICR. The incidence of MI (0.2% vs. 3.1%, risk difference 2.9%, 95%CI 1.2 to 4.5, $p <$
220 0.001) and unplanned ischemia driven revascularization (0.9% vs. 3.7%, risk difference 2.9%, 95%CI 0.9 to 4.8, $p =$
221 0.004) was also lower in the patients randomized to ICR at 30-day follow-up. All spontaneous MIs between the
222 index and staged procedure occurred in patients that initially presented with NSTEMI-ACS. Additionally, there was a
223 higher incidence of the composite of all-cause mortality, MI, stroke or major bleeding (BARC 3 or 5) in the SCR
224 arm (1.3% vs. 5.7%, risk difference 4.4%, 95%CI 2.0 to 6.8, $p < 0.001$). The primary and secondary outcomes at 30
225 days are tabulated in Table 3.

226

227 The cumulative incidence of the primary composite outcome at 1 year follow-up was 7.9% and 10.1% in the patients
228 randomized to ICR and SCR (risk difference 2.2%, 95% confidence interval [CI] -1.5 to 6.0, $p = 0.24$). The incidence
229 of cardiovascular death at 1 year was similar between the two trial arms (1.1% vs. 0.9%, risk difference -0.2%,
230 95%CI -1.5 to 1.1, $p = 0.75$). The composite of cardiovascular death and MI occurred in 3.1% and 5.7% of the
231 patients at 1 year, (risk difference 2.7%, 95%CI 0.0 to 5.3, $p = 0.052$). ICR was associated with a lower incidence of
232 MI (2.0% vs. 5.3%, risk difference 3.3%, 95%CI 0.9 to 5.7, $p = 0.008$) and unplanned ischemia driven
233 revascularization (4.2% vs. 7.8%, risk difference 3.5%, 95%CI 0.4 to 6.6, $p = 0.025$) at 1 year. The primary and
234 secondary outcomes at 1 year are tabulated in Table 4.

235

236 An analysis excluding procedure related MIs occurring during the index or staged procedure was performed due to
237 the possibility of a potential bias caused by the difficulty of diagnosing type 4a MIs during the index event. This
238 analysis consistently showed a significant reduction of MIs in the ICR group (2.0% vs. 4.4%, risk difference 2.4%,
239 95%CI 0.1 to 4.7, $p = 0.039$). A total of 13 non procedure related infarctions occurred between the index and staged

240 procedure, of which 10 were type 1, 1 was type 2 and 2 were type 4b MIs. The primary and secondary outcomes at 1
241 year, excluding type 4a MIs related to the index or staged procedure, are tabulated in Table 5.

242 243 **Discussion**

244
245 The current further analysis of the BIOVASC trial, which was prespecified in the trial protocol, suggests a reduction
246 in the incidence of MIs and unplanned ischemia driven revascularizations at 1 year post index PCI when performing
247 ICR in the NSTEMI-ACS population. The reduction in myocardial infarction associated with an ICR strategy persisted
248 after exclusion of procedure-related events.

249
250 In the BIOVASC trial, 44% (N=15) of all first occurring non procedure related MIs in the SCR group, happened
251 between the index and staged procedure. Ten of those MIs were type 1 MI and occurred only in patients that initially
252 presented with a NSTEMI-ACS at randomization.

253
254 Plaque vulnerability of non-culprit lesions might have a role in the occurrence of early spontaneous infarctions in
255 patients with ACS. Several factors could induce plaque instability in the acute phase, such as an enhanced general
256 inflammatory status, oxidative stress, which is an imbalance between the generation of reactive oxygen species and
257 its clearance through the intrinsic antioxidant defense system²⁰. Acute MI has been associated with a decrease in
258 antioxidant enzymes²¹, potentially impacting plaque vulnerability in non-culprit lesions. Several studies in ACS and
259 MVD patients^{22,23} showed the presence of thin-cap fibroatheroma in up to 40% of the analyzed obstructive non-
260 culprit lesions, which is associated with a higher risk of future cardiac events²⁴.

261 The non-culprit lesion vulnerability remains yet to be fully evaluated in NSTEMI-ACS, but a role of diffuse
262 inflammation and plaque instability cannot be excluded in the pathogenesis of the early ischemic events in our
263 population.

264
265 Another distinct mechanism that could also explain early ischemic events is the incorrect culprit lesion identification
266 during the index procedure. At variance with STEMI patients in whom the culprit lesion is angiographically evident
267 in the vast majority of the cases, in NSTEMI-ACS and multivessel disease, culprit lesion assessment can be very
268 challenging^{25,26}. Despite the fact that unclear culprit lesion was an exclusion criteria in the BIOVASC trial,
269 misjudgment of the culprit lesion could have occurred, leading to some acute plaques being left untreated possibly
270 triggering a second early event between the index and staged procedure²⁷.

271
272 This difference in culprit lesion identification between STEMI and NSTEMI-ACS patients might also explain the
273 dissimilar progression of the time-to-event curves in this study compared with the COMPLETE trial¹⁹ in which in
274 the culprit-only revascularization group, events accrued over time in the long-term follow-up.

275

276 The SMILE trial showed a significant reduction of the composite of mortality, MI, re-hospitalization for unstable
277 angina, target vessel revascularization and stroke at 1 year when performing ICR instead of SCR in patients
278 presenting with NSTEMI-ACS and MVD¹⁵. This effect was driven by a lower risk of target vessel revascularization in
279 the ICR group. In contrast to our study, the time-to-event curves did not diverge early in the follow-up period, but
280 only after 100 days. This discrepancy might be caused by the different study designs. In our study the median time
281 to the staged procedure was 15 days, which is a longer interval than the mean 4.8 days in the SMILE trial,
282 potentially leading to more events in the 30 day timeframe. However, when comparing the results of the SMILE
283 study with ours, the difference in total event rates must also be taken into account. Our study showed a total event
284 rate of 8.9% for the primary composite endpoint, as opposed to 18.4% in the SMILE study driven by a remarkably
285 high rate of target vessel revascularization (15.4% at 1 year follow-up)²⁸.

286
287 Similarly to our study, an analysis from the CREDO-Kyoto registry showed significantly lower myocardial
288 infarctions and revascularizations occurring in the ICR group at 30 days post index PCI²⁹. At 5 years the study
289 showed no difference in the composite primary outcome or any of its individual components, but both the incidence
290 curves and 30-day results, suggest a similar temporal progression of events compared with our study.

291
292 Our data support the adoption of an ICR approach in NSTEMI-ACS and MVD. In this sub-population of the
293 BIOVASC trial the clinical benefit of ICR was evident in terms of MIs and unplanned ischemia-driven
294 revascularizations regardless of procedure-related events. In addition, similarly to the BIOVASC trial, in the present
295 subanalysis the ICR approach was associated with a reduction in total hospital stay, suggesting possible health
296 economic implications in NSTEMI-ACS patients³⁰.

297
298 *Limitations*

299 This is a pre-specified post-hoc analysis of a randomized noninferiority trial. No formal power calculation was
300 performed for this analysis. The use of intracoronary imaging was low, reflecting the current European clinical
301 practice. A higher adoption of imaging might have had an impact on culprit lesion identification providing further
302 insights on the mechanism of early ischemic events.

303
304 **Conclusions**

305 In patients presenting with NSTEMI-ACS and MVD, immediate complete revascularization was safe and associated
306 with a lower cumulative incidence of myocardial infarctions and unplanned ischemia driven myocardial infarction at
307 1 year post index PCI compared with staged complete revascularization.

308

309

310

311 **References**

312

- 313 1. Thiele H, Rach J, Klein N, Pfeiffer D, Hartmann A, Hambrecht R, Sick P, Eitel I, Desch S, Schuler G, et al.
314 Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig
315 Immediate versus early and late Percutaneous coronary Intervention trial in NSTEMI (LIPSIA-NSTEMI
316 Trial). *European Heart Journal*. 2011;33:2035-2043. doi: 10.1093/eurheartj/ehr418
- 317 2. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective
318 randomised multicentre study. *The Lancet*. 1999;354:708-715. doi: [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(99)07349-3)
319 [6736\(99\)07349-3](https://doi.org/10.1016/S0140-6736(99)07349-3)
- 320 3. Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, Kalra SS, Dalby MC, O'Mahony C,
321 Malik IS, et al. Complete Versus Culprit-Only Lesion Intervention in Patients With Acute Coronary
322 Syndromes. *Journal of the American College of Cardiology*. 2018;72:1989-1999. doi:
323 <https://doi.org/10.1016/j.jacc.2018.07.089>
- 324 4. Corpus RA, House JA, Marso SP, Grantham JA, Huber KC, Laster SB, Johnson WL, Daniels WC, Barth
325 CW, Giorgi LV, et al. Multivessel percutaneous coronary intervention in patients with multivessel disease
326 and acute myocardial infarction. *American Heart Journal*. 2004;148:493-500. doi:
327 <https://doi.org/10.1016/j.ahj.2004.03.051>
- 328 5. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple Complex Coronary
329 Plaques in Patients with Acute Myocardial Infarction. *New England Journal of Medicine*. 2000;343:915-
330 922. doi: 10.1056/nejm200009283431303
- 331 6. Fox KAA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JGP, Lagerqvist B, Wallentin L.
332 Long-Term Outcome of a Routine Versus Selective Invasive Strategy in Patients With Non-ST-Segment
333 Elevation Acute Coronary Syndrome: A Meta-Analysis of Individual Patient Data. *Journal of the American*
334 *College of Cardiology*. 2010;55:2435-2445. doi: <https://doi.org/10.1016/j.jacc.2010.03.007>
- 335 7. Jobs A, Mehta SR, Montalescot G, Vicaut E, van't Hof AWJ, Badings EA, Neumann F-J, Kastrati A,
336 Sciahbasi A, Reuter P-G, et al. Optimal timing of an invasive strategy in patients with non-ST-elevation
337 acute coronary syndrome: a meta-analysis of randomised trials. *The Lancet*. 2017;390:737-746. doi:
338 [https://doi.org/10.1016/S0140-6736\(17\)31490-3](https://doi.org/10.1016/S0140-6736(17)31490-3)
- 339 8. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann F-J, Robertson DH,
340 DeLucca PT, DiBattiste PM, et al. Comparison of Early Invasive and Conservative Strategies in Patients
341 with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban. *New*
342 *England Journal of Medicine*. 2001;344:1879-1887. doi: 10.1056/nejm200106213442501
- 343 9. Poole-Wilson PA, Pocock SJ, Fox KAA, Henderson RA, Wheatley DJ, Chamberlain DA, Shaw TRD,
344 Clayton TC. Interventional versus conservative treatment in acute non-ST elevation coronary syndrome:

- 345 time course of patient management and disease events over one year in the RITA 3 trial. *Heart*.
346 2006;92:1473-1479. doi: 10.1136/hrt.2005.060541
- 347 10. Wallentin L, Lindhagen L, Årnström E, Husted S, Janzon M, Johnsen SP, Kontny F, Kempf T, Levin L-Å,
348 Lindahl B, et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute
349 coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. *The*
350 *Lancet*. 2016;388:1903-1911. doi: [https://doi.org/10.1016/S0140-6736\(16\)31276-4](https://doi.org/10.1016/S0140-6736(16)31276-4)
- 351 11. Kim MC, Hyun JY, Ahn Y, Bae S, Hyun DY, Cho KH, Sim DS, Hong YJ, Kim JH, Jeong MH, et al.
352 Optimal Revascularization Strategy in Non-ST-Segment-Elevation Myocardial Infarction With Multivessel
353 Coronary Artery Disease: Culprit-Only Versus One-Stage Versus Multistage Revascularization. *J Am*
354 *Heart Assoc*. 2020;9:e016575.
- 355 12. Ibrahim H, Sharma PK, Cohen DJ, Fonarow GC, Kaltenbach LA, Effron MB, Zettler ME, Peterson ED,
356 Wang TY. Multivessel Versus Culprit Vessel-Only Percutaneous Coronary Intervention Among Patients
357 With Acute Myocardial Infarction: Insights From the TRANSLATE-ACS Observational Study. *J Am Heart*
358 *Assoc*. 2017;6.
- 359 13. Zapata GO, Lasave LI, Kozak F, Damonte A, Meiriño A, Rossi M, Carbó S, Pollice A, Paolasso E, Picabea
360 E. Culprit-only or multivessel percutaneous coronary stenting in patients with non-ST-segment elevation
361 acute coronary syndromes: one-year follow-up. *J Interv Cardiol*. 2009;22:329-335.
- 362 14. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M,
363 Edvardsen T, Folliguet T, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in
364 patients presenting without persistent ST-segment elevation: The Task Force for the management of acute
365 coronary syndromes in patients presenting without persistent ST-segment elevation of the European
366 Society of Cardiology (ESC). *European Heart Journal*. 2020;42:1289-1367. doi:
367 10.1093/eurheartj/ehaa575
- 368 15. Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, Calcagno S, Ugo F, Boccuzzi G,
369 Fedele F, et al. Single-Stage Compared With Multi-Stage PCI in Multivessel NSTEMI Patients: The
370 SMILE Trial. *J Am Coll Cardiol*. 2016;67:264-272.
- 371 16. Diletti R, den Dekker WK, Bennett J, Schotborgh CE, van der Schaaf R, Sabaté M, Moreno R, Ameloot K,
372 van Bommel R, Forlani D, et al. Immediate versus staged complete revascularisation in patients presenting
373 with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label,
374 non-inferiority, randomised trial. *The Lancet*. doi: 10.1016/s0140-6736(23)00351-3
- 375 17. den Dekker WK, Van Mieghem NM, Bennett J, Sabate M, Esposito G, van Bommel RJ, Daemen J, Vrolix
376 M, Cummins PA, Lenzen MJ, et al. Percutaneous complete revascularization strategies using sirolimus-
377 eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and
378 multivessel disease: Rationale and design of the BIOVASC trial. *Am Heart J*. 2020;227:111-117.
- 379 18. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint
380 ESCAAHAWHFTFtUDoMI, Katus HA, Lindahl B, Morrow DA, et al. Third universal definition of
381 myocardial infarction. *Circulation*. 2012;126:2020-2035.

- 382 19. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B, Di Pasquale G, López-
383 Sendón J, Faxon DP, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. *N*
384 *Engl J Med*. 2019;381:1411-1421.
- 385 20. Vichova T, Motovska Z. Oxidative stress: Predictive marker for coronary artery disease. *Exp Clin Cardiol*.
386 2013;18:e88-91.
- 387 21. Rodrigo R, Libuy M, Feliú F, Hasson D. Oxidative Stress-Related Biomarkers in Essential Hypertension
388 and Ischemia-Reperfusion Myocardial Damage. *Disease Markers*. 2013;35:974358. doi:
389 10.1155/2013/974358
- 390 22. Natalia P-E, Shamir RM, Jia W, Shahar L, Erick S, Warren JC, Kevin RB, Robert CW, Saleem K, Roxana
391 M, et al. Nonculprit Lesion Plaque Morphology in Patients With ST-Segment–Elevation Myocardial
392 Infarction. *Circulation: Cardiovascular Interventions*. 2020;13:e008768. doi:
393 doi:10.1161/CIRCINTERVENTIONS.119.008768
- 394 23. Kedhi E, Berta B, Roleder T, Hermanides RS, Fabris E, Ijsselmuiden AJJ, Kauer F, Alfonso F, von
395 Birgelen C, Escaned J, et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with
396 normal fractional flow reserve: the COMBINE OCT–FFR trial. *European Heart Journal*. 2021;42:4671-
397 4679. doi: 10.1093/eurheartj/ehab433
- 398 24. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N,
399 Marso SP, et al. A Prospective Natural-History Study of Coronary Atherosclerosis. *New England Journal*
400 *of Medicine*. 2011;364:226-235. doi: 10.1056/NEJMoa1002358
- 401 25. Balbi MM, Scarparo P, Tovar MN, Masdjedi K, Daemen J, Den Dekker W, Ligthart J, Witberg K,
402 Cummins P, Wilschut J, et al. Culprit Lesion Detection in Patients Presenting With Non-ST Elevation
403 Acute Coronary Syndrome and Multivessel Disease. *Cardiovascular Revascularization Medicine*.
404 2022;35:110-118. doi: <https://doi.org/10.1016/j.carrev.2021.03.019>
- 405 26. John FH, Annamalai S, Harrison JK, Igor K, Michael HS, Alexandr I, Carine H, Lowie Van A, James W,
406 Jeffrey W, et al. Identifying the Infarct-Related Artery in Patients With Non–ST-Segment–Elevation
407 Myocardial Infarction. *Circulation: Cardiovascular Interventions*. 2019;12:e007305. doi:
408 doi:10.1161/CIRCINTERVENTIONS.118.007305
- 409 27. Di Gioia G, Toth G, Rusinaru D, Pellicano M, Wijns W, De Bruyne B, Barbato E. Acute coronary
410 syndromes in patients with multivessel disease: the key role of optical coherence tomography. *Journal of*
411 *Cardiovascular Medicine*. 2016;17.
- 412 28. Henriques JP, Claessen BE. A SMILE and a Frown: One-Stage or Multistage PCI in NSTEMI Patients
413 With Multivessel Disease. *J Am Coll Cardiol*. 2016;67:273-274.
- 414 29. Toyota T, Morimoto T, Shiomi H, Yamaji K, Ando K, Ono K, Shizuta S, Saito N, Kato T, Kaji S, et al.
415 Single-session versus staged procedures for elective multivessel percutaneous coronary intervention. *Heart*.
416 2018;104:936-944.

- 417 30. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang
418 AR, Cheng S, Delling FN, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the
419 American Heart Association. *Circulation*. 2020;141:e139-e596.
420
421

422 **Tables and Figures**

Table 1. Baseline Characteristics.

| Characteristics | Immediate Complete Revascularization (N=459) | Staged Complete Revascularization (N=458) | P Value |
|--------------------------------|---|--|----------------|
| Age, years | 67.0 (58.1–74.3) | 66.8 (59.3–73.9) | 0.62 |
| Male sex | 350 (76.3%) | 355 (77.5%) | 0.65 |
| BMI | 27.3 (24.5–30.4) | 27.5 (25.0–30.0) | 0.80 |
| Presentation | | | 0.25 |
| NSTEMI | 402 (87.6%) | 388 (84.7%) | |
| UA | 57 (12.4%) | 70 (15.3%) | |
| Medical history | | | |
| Previous PCI | 61 (13.3%) | 82 (17.9%) | 0.054 |
| History of MI | 53/458 (11.6%) | 65/458 (14.2%) | 0.24 |
| Peripheral artery disease | 27 (5.9%) | 23 (5.0%) | 0.57 |
| COPD | 38 (8.3%) | 34 (7.4%) | 0.63 |
| Atrial fibrillation or flutter | 23 (5.0%) | 17 (3.7%) | 0.34 |
| Renal insufficiency | 32 (7.0%) | 31 (6.8%) | 0.90 |
| History of stroke | 25 (5.5%) | 18 (3.9%) | 0.28 |
| Hypertension | 286 (62.3%) | 266 (58.1%) | 0.19 |
| Diabetes | 107 (23.3%) | 117 (25.5%) | 0.43 |
| Hypercholesterolemia | 261/457 (57.1%) | 270 (59.0%) | 0.57 |
| Family history of CVD | 150/458 (32.8%) | 151/451 (33.5%) | 0.82 |
| Smoking behavior | | | 0.57 |
| Never | 216/455 (47.5%) | 218/454 (48.0%) | |
| Current | 144/455 (31.6%) | 131/454 (28.9%) | |
| Former | 95/455 (20.9%) | 105/454 (23.1%) | |

Data are presented as median (Q1, Q3), n (%), or n/N (%). BMI indicates body-mass index; COPD, chronic obstructive coronary disease; CVD, cardiovascular disease; IQR, interquartile range; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; UA, unstable angina

423
424
425
426

Table 2. Procedural Characteristics

| Characteristics | Immediate Complete Revascularization (N=459) | Staged Complete Revascularization (N=458) | P Value |
|--|---|--|----------------|
| Systolic blood pressure, mmHg | 127 (111–140) | 126 (110–140) | 0.67 |
| Diastolic blood pressure, mmHg | 71 (63–80) | 70 (62–80) | 0.11 |
| Radial access | 448/458 (97.8%) | 440/458 (96.1%) | 0.12 |
| Location of culprit lesion* | | | 0.38 |
| Left main coronary artery | 2/452 (0.4%) | 5/457 (1.1%) | |
| Left anterior descending artery | 173/452 (38.3%) | 154/457 (33.7%) | |
| Circumflex artery | 140/452 (31.0%) | 147/457 (32.3%) | |
| Right coronary artery | 137/452 (30.3%) | 151/457 (33.0%) | |
| No. of vessels with significant non-culprit lesions† | | | 0.11 |
| 1 | 367/431 (85.2%) | 343/423 (81.1%) | |
| ≥2 | 64/431 (14.8%) | 80/423 (18.9%) | |
| Lesion complexity‡ | | | 0.27 |
| Type A | 116/921 (12.6%) | 112/908 (12.3%) | |
| Type B1 | 305/921 (33.1%) | 266/908 (29.3%) | |
| Type B2 | 217/921 (23.6%) | 220/908 (24.2%) | |
| Type C | 283/921 (30.7%) | 310/908 (34.1%) | |
| Complete revascularization¶ | 448/459 (97.6%) | 435/457 (95.2%) | 0.0496 |
| FFR/iFR | 77 (16.8%) | 122 (26.6%) | <0.001 |
| IVUS/OCT | 22 (4.8%) | 69 (15.1%) | <0.001 |
| Total hospital stay, days | 3 (2–5) | 4 (3–6) | <0.001 |
| Time to staged procedure, days | NA | 15 (4–28) | |
| No. of stents used per patient | | | |
| Index procedure | 3 (2–3.5) | 1 (1–2) | <0.001 |
| Index + staged procedure | 3 (2–3.5) | 3 (2–4) | 0.059 |
| Length of stents, mm | | | |
| Index procedure | 57.5 (41–82) | 30 (18–44) | <0.001 |
| Index + staged procedure | 57.5 (41–82) | 66 (44–90) | 0.025 |
| Index procedure duration, minutes | 68 (48.5–85) | 50 (36–85) | <0.001 |
| Index + staged procedure duration, minutes | 68 (48.5–85) | 91 (65–122) | <0.001 |
| Index procedure contrast use, mL | 206.5 (154.5–270) | 144.5 (101–190) | <0.001 |
| Index + staged procedure contrast use, mL | 206.5 (154.5–270) | 250 (196–330) | <0.001 |
| Index procedure total area dose, cGycm ² | 4731 (2476–12495) | 3087 (1561–6622) | <0.001 |
| Index + staged procedure total area dose, cGycm ² | 4731 (2476–12495) | 6271 (3577–16703) | 0.001 |
| P2Y12 inhibitor at discharge‡ | | | 0.38 |
| Ticagrelor | 334/458 (72.9%) | 328/456 (71.9%) | |
| Prasugrel | 32/458 (7.0%) | 43/456 (9.4%) | |
| Clopidogrel | 92/458 (20.1) | 85/456 (18.6%) | |

Data are median (Q1,Q3), n (%), or n/N (%). NA=not applicable. *In seven patients the culprit was unclear and one patient was randomized but had no coronary artery disease. †In total, 63 patients had no significant multivessel disease when physiological assessment was performed after randomization. ‡The total number of vessels with significant lesions (with vessel diameter ≥ 2.5 mm) was 1933. The lesion complexity was not reported for 104 lesions (5.4%). ¶A patient was considered completely revascularized if all significant lesions with vessel diameter ≥ 2.5 mm were treated and showed a final Thrombolysis in Myocardial Infarction grade 3. One patient withdrew consent before the staged procedure, therefore completeness of revascularization could not be ascertained. ‡One

patient died before discharge so no medications were prescribed; one patient was discharged with single antiplatelet therapy and anticoagulation (aspirin and warfarin); and one patient did not have coronary artery disease and was not treated with antiplatelet therapy.

427
428
429

Table 3. Primary and Secondary Outcomes at 30 Days.

| Outcome | Immediate Complete Revascularization (N=459) | | Staged Complete Revascularization (N=458) | | Hazard Ratio (95% CI) | Risk difference (95% CI) ‡ | P Value |
|--|--|--------------|---|--------------|-----------------------|----------------------------|---------|
| | No. events | Percentage † | No. events | Percentage † | | | |
| Primary outcome | | | | | | | |
| All-cause mortality, any myocardial infarction, unplanned ischemia driven revascularization or cerebrovascular event | 8 | 1.8% | 26 | 5.7% | 0.30 (0.13, 0.66)* | 4.0% (1.5, 6.4) | 0.002 |
| Secondary outcomes | | | | | | | |
| Cardiovascular mortality or myocardial infarction | 2 | 0.4% | 15 | 3.3% | 0.13 (0.03, 0.57) | 2.9% (1.1, 4.6) | 0.001 |
| All-cause mortality | 2 | 0.4% | 2 | 0.4% | 1.00 (0.14, 7.07) | 0.0% (-0.9, 0.9) | >0.99 |
| Cardiovascular mortality | 1 | 0.2% | 2 | 0.4% | 0.50 (0.05, 5.49) | 0.2% (-0.5, 1.0) | 0.56 |
| Any myocardial infarction | 1 | 0.2% | 14 | 3.1% | 0.07 (0.01, 0.53) | 2.9% (1.2, 4.5) | <0.001 |
| Unplanned ischemia driven revascularization | 4 | 0.9% | 17 | 3.7% | 0.23 (0.08, 0.68)* | 2.9% (0.9, 4.8) | 0.004 |
| Cerebrovascular event | 2 | 0.4% | 7 | 1.5% | 0.28 (0.06, 1.36) | 1.1% (-0.2, 2.4) | 0.09 |
| Probable or definite stent thrombosis | 2 | 0.4% | 3 | 0.7% | 0.66 (0.11, 3.97) | 0.2% (-0.7, 1.2) | 0.65 |
| Target vessel revascularization | 4 | 0.9% | 17 | 3.7% | 0.23 (0.08, 0.68)* | 2.9% (0.9, 4.8) | 0.004 |
| Target lesion revascularization | 4 | 0.9% | 15 | 3.3% | 0.26 (0.09, 0.79)* | 2.4% (0.6, 4.3) | 0.010 |
| All-cause mortality, myocardial infarction, stroke or major bleeding (BARC 3 or 5) | 6 | 1.3% | 26 | 5.7% | 0.22 (0.09, 0.54)* | 4.4% (2.0, 6.8) | <0.001 |
| Major bleeding (BARC 3 or 5) | 1 | 0.2% | 5 | 1.1% | 0.20 (0.02, 1.70) | 0.9% (-0.2, 1.9) | 0.10 |

BARC=bleeding academic research consortium. * The cox proportional hazard assumption was not met † Cumulative incidence at 365 days according to the Kaplan-Meier method. ‡ Based on the Kaplan-Meier estimates. A difference in favour of immediate complete revascularization is presented as a positive value. § This P value was tested for superiority of the risk difference.

430
431
432

Table 4. Primary and Secondary Outcomes at 1 Year.

| Outcome | Immediate Complete Revascularisation (N=459) | | Staged Complete Revascularisation (N=458) | | Hazard Ratio (95% CI) | Risk difference (95% CI) ‡ | P Value |
|--|--|--------------|---|--------------|-----------------------|----------------------------|---------|
| | No. events | Percentage † | No. events | Percentage † | | | |
| Primary outcome | | | | | | | |
| All-cause mortality, any myocardial infarction, unplanned ischemia driven revascularization or cerebrovascular event | 36 | 7.9% | 46 | 10.1% | 0.75 (0.48, 1.16)* | 2.2% (-1.5, 6.0) | 0.24 |
| Secondary outcomes | | | | | | | |
| Cardiovascular mortality or myocardial infarction | 14 | 3.1% | 26 | 5.7% | 0.52 (0.27, 1.00)* | 2.7% (0.0, 5.3%) | 0.052 |
| All-cause mortality | 7 | 1.5% | 5 | 1.1% | 1.39 (0.44, 4.38) | -0.4% (-1.9, 1.1) | 0.57 |
| Cardiovascular mortality | 5 | 1.1% | 4 | 0.9% | 1.24 (0.33, 4.62) | -0.2% (-1.5, 1.1) | 0.75 |
| Myocardial infarction | 9 | 2.0% | 24 | 5.3% | 0.36 (0.17, 0.78)* | 3.3% (0.9, 5.7) | 0.008 |
| Unplanned ischemia driven revascularization | 19 | 4.2% | 35 | 7.8% | 0.52 (0.30, 0.91)* | 3.5% (0.4, 6.6) | 0.025 |
| Cerebrovascular event | 7 | 1.6% | 8 | 1.8% | 0.86 (0.31, 2.38)* | 0.2% (-1.5, 1.9) | 0.81 |
| Probable or definite stent thrombosis | 2 | 0.4% | 5 | 1.1% | 0.40 (0.08, 2.05) | 0.7% (-0.5, 1.8) | 0.25 |
| Target vessel revascularization | 16 | 3.6% | 33 | 7.3% | 0.47 (0.26, 0.85)* | 3.8% (0.8, 6.7) | 0.013 |
| Target lesion revascularization | 13 | 2.9% | 30 | 6.7% | 0.42 (0.22, 0.80)* | 3.8% (1.0, 6.6) | 0.007 |
| All-cause mortality, myocardial infarction, stroke or major bleeding (BARC 3 or 5) | 30 | 6.6% | 40 | 8.8% | 0.72 (0.45, 1.15)* | 2.2% (-1.2, 5.7) | 0.21 |
| Major bleeding (BARC 3 or 5) | 8 | 1.8% | 9 | 2.0% | 0.88 (0.34, 2.28) | 0.2% (-1.5, 2.0) | 0.79 |

BARC=bleeding academic research consortium. * The cox proportional hazard assumption was not met † Cumulative incidence at 365 days according to the Kaplan-Meier method. ‡ Based on the Kaplan-Meier estimates. A difference in favour of immediate complete revascularization is presented as a positive value. § This P value was tested for superiority of the risk difference.

433
434
435
436
437
438
439
440

441
442
443
444
445
446
447
448


Table 5. Clinical Outcomes Excluding Index and Staged Procedure Related Myocardial Infarctions

| Outcome | Immediate Complete Revascularization (N=459) | | Staged Complete Revascularization (N=458) | | Hazard Ratio (95% CI) | Risk difference (95% CI) ‡ | P Value |
|--|--|--------------|---|--------------|-----------------------|----------------------------|---------|
| | No. events | Percentage † | No. events | Percentage † | | | |
| All-cause mortality, myocardial infarction, unplanned ischemia driven revascularization or cerebrovascular event | 36 | 7.9% | 43 | 9.5% | 0.80 (0.52, 1.25)* | 1.6% (-2.1, 5.2) | 0.40 |
| Cardiovascular mortality or myocardial infarction | 14 | 3.1% | 22 | 4.9% | 0.62 (0.32, 1.21)* | 1.8% (-0.8, 4.3) | 0.17 |
| Myocardial infarction | 9 | 2.0% | 20 | 4.4% | 0.44 (0.20, 0.96)* | 2.4% (0.1, 4.7) | 0.039 |
| All-cause mortality, myocardial infarction, stroke or major bleeding (BARC 3 and 5) | 30 | 6.6% | 37 | 8.2% | 0.78 (0.48, 1.26) | 1.6% (-1.8, 5.0) | 0.37 |

BARC=bleeding academic research consortium. * The cox proportional hazard assumption was not met † Cumulative incidence at 365 days according to the Kaplan-Meier method. ‡ Based on the Kaplan-Meier estimates. A difference in favour of immediate complete revascularization is presented as a positive value. § This P value was tested for superiority of the risk difference.

449
450
451
452
453
454
455
456
457
458
459
460
461


462 **Figure 1. Outcomes**
463



464 **Caption:** The primary outcome is a composite of all-cause mortality, myocardial infarction,
465
466 unplanned ischemia driven revascularization and cerebrovascular events. A difference in favour

467 of immediate complete revascularization is presented as a positive value. ICR indicates
468 immediate complete revascularization; SCR, staged complete revascularization.
469
470


471 **Figure 2. Myocardial Infarction Excluding Procedure Related Myocardial Infarctions**



472
 473 **Caption:** Type 4a myocardial infarctions related to the index and staged procedure were
 474 excluded from the analysis. A difference in favour of immediate complete revascularization is
 475 presented as a positive value. ICR indicates immediate complete revascularization; SCR, staged
 476 complete revascularization.

477
 478


479 **Figure 3. Thrombosis of Non-Culprit in Between the Index and Staged Procedure.**



480
481
482 **Caption:** A patient in their 70s presented with a NSTEMI. Coronary angiogram revealed
483 subtotal lesions in the RCA (panel A), a significant lesion in the diagonal branch (panel C) and
484 in-stent restenosis of the LCX. After intravascular imaging the lesion in the RCA was identified
485 as the culprit lesion (panel B).
486 The patient was randomized to staged complete revascularization. The RCA was treated
487 successfully and non-culprit lesion treatment was planned after 14 days.
488 At day 8 post index PCI, the patient presented at the emergency due to chest pain. New coronary
489 angiography showed that the significant non-culprit lesion in the diagonal had evolved into a
490 thrombotic occlusion (panel D).
491 D1 indicates first diagonal; LCX, left circumflex artery; NSTEMI, non-ST-elevation myocardial
492 infarction; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; RCA,
493 right coronary artery.
494

A Primary Composite Outcome

Immediate complete revascularization vs. Staged complete revascularization
 Risk difference 2.2%, 95% CI [-1.5, 6.0], p = 0.24




Number at risk

| | 0 | 30 | 60 | 90 | 120 | 150 | 180 | 210 | 240 | 270 | 300 | 330 | 360 |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ICR | 459 | 448 | 448 | 446 | 446 | 446 | 442 | 439 | 436 | 433 | 427 | 423 | 393 |
| SCR | 458 | 428 | 424 | 420 | 418 | 416 | 414 | 411 | 411 | 409 | 408 | 406 | 379 |

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.29.23290502>; this version posted May 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

B Myocardial Infarction

Immediate complete revascularization vs. Staged complete revascularization
 Risk difference 3.3%, 95% CI [0.9, 5.7], p = 0.008




Number at risk

| | 0 | 30 | 60 | 90 | 120 | 150 | 180 | 210 | 240 | 270 | 300 | 330 | 360 |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ICR | 459 | 453 | 453 | 453 | 453 | 453 | 449 | 448 | 448 | 447 | 444 | 441 | 412 |
| SCR | 458 | 439 | 434 | 431 | 430 | 429 | 429 | 427 | 427 | 426 | 426 | 424 | 396 |

C Unplanned Ischemia Driven Revascularization

Immediate complete revascularization vs. Staged complete revascularization
 Risk difference 3.5%, 95% CI [0.4, 6.6], p = 0.025




Number at risk

| | 0 | 30 | 60 | 90 | 120 | 150 | 180 | 210 | 240 | 270 | 300 | 330 | 360 |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ICR | 459 | 450 | 450 | 448 | 448 | 448 | 445 | 443 | 440 | 437 | 433 | 430 | 403 |
| SCR | 458 | 435 | 432 | 429 | 426 | 424 | 422 | 419 | 419 | 417 | 416 | 414 | 387 |

MI Excluding Procedure Related MI

Immediate complete revascularization vs. Staged complete revascularization
 Risk difference 2.4%, 95% CI [0.1, 4.7], p = 0.039

Cumulative event rate




Number at risk

| | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ICR | 459 | 453 | 453 | 453 | 453 | 453 | 449 | 448 | 448 | 447 | 444 | 441 | 412 |
| SCR | 458 | 442 | 438 | 435 | 434 | 433 | 433 | 431 | 431 | 430 | 430 | 428 | 400 |
| | 0 | 30 | 60 | 90 | 120 | 150 | 180 | 210 | 240 | 270 | 300 | 330 | 360 |

A Culprit lesion in the RCA



B OCT imaging of the RCA



C Non-culprit lesion in the D1 at index



D At day 8, Non-culprit lesion thrombosis

